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Association Between APOL1 Genotypes and Risk of Cardiovascular
Disease in MESA (Multi-Ethnic Study of Atherosclerosis)
Teresa K. Chen, MD, MHS; Ronit Katz, DPhil; Michelle M. Estrella, MD, MHS; Orlando M. Gutierrez, MD, MMSc; Holly Kramer, MD, MPH;
Wendy S. Post, MD, MS; Michael G. Shlipak, MD, MPH; Christina L. Wassel, PhD; Carmen A. Peralta, MD, MAS
Background-—APOL1 genetic variants confer an increased risk for kidney disease. Their associations with cardiovascular disease
(CVD) are less certain. We aimed to compare the prevalence of subclinical CVD and incidence of atherosclerotic CVD and heart
failure by APOL1 genotypes among self-identified black participants of MESA (Multi-Ethnic Study of Atherosclerosis).
Methods and Results-—Cross-sectional associations of APOL1 genotypes (high-risk=2 alleles; low-risk=0 or 1 allele) with coronary
artery calcification, carotid-intimal media thickness, and left ventricular mass were evaluated using logistic and linear regression.
Longitudinal associations of APOL1 genotypes with incident myocardial infarction, stroke, coronary heart disease, and congestive
heart failure were examined using Cox regression. We adjusted for African ancestry, age, and sex. We also evaluated whether
hypertension or kidney functionmarkers explained the observed associations. Among 1746participants withAPOL1 genotyping (mean
age 62 years, 55% women, mean cystatin C–based estimated glomerular filtration rate 89 mL/min per 1.73 m2, 12% with
albuminuria), 12% had the high-risk genotypes.We found no difference in prevalence or severity of coronary artery calcification, carotid-
intimal media thickness, or left ventricular mass by APOL1 genotypes. The APOL1 high-risk group was 82% more likely to develop
incident heart failure compared with the low-risk group (95% confidence interval, 1.01–3.28). Adjusting for hypertension (hazard ratio,
1.80; 95% confidence interval, 1.00–3.24) but not markers of kidney function (hazard ratio, 1.86; 95% confidence interval, 1.03–3.35)
slightly attenuated this association. TheAPOL1 high-risk genotypeswere not significantly associatedwith other clinical CVDoutcomes.
Conclusions-—Among blacks without baseline CVD, the APOL1 high-risk variants may be associated with increased risk for
incident heart failure but not subclinical CVD or incident clinical atherosclerotic CVD. ( J Am Heart Assoc. 2017;6:e007199. DOI:
10.1161/JAHA.117.007199.)
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B lack people are significantly more likely to develop end-stage renal disease compared with other races, even
after accounting for traditional risk factors for kidney
disease.1–3 This excess burden of progressive kidney disease
has been attributed, in part, to the higher prevalence of
variants in the gene encoding for apolipoprotein L1 (APOL1),
located on chromosome 22, among self-identified blacks.4–9
The APOL1 risk variants (G1 and G2), which confer protection
against African sleeping sickness,4,5,10 are associated with
increased risk for various types of kidney disease, including
focal segmental glomerulosclerosis,11 HIV-associated
nephropathy,11,12 lupus nephritis,13 hypertension-attributed
chronic kidney disease,6 and possibly accelerated progression
of diabetic kidney disease.7
While significant advances have been made in our under-
standing of APOL1-associated kidney disease,14 the specific
mechanisms by which these genetic variants cause kidney
disease remain uncertain. Because of the elevated risks for
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cardiovascular disease (CVD) and heart failure (HF) among
people with chronic kidney disease compared with the general
population,15 investigation of the cardiovascular risk of
individuals who carry the APOL1 high-risk variants is an issue
of active study. Apolipoprotein L1 (Apol1) has been localized to
endothelial and vascular smooth muscle cells within the
kidney16,17 and is also known to circulate in plasma with
high-density lipoprotein particles,18,19 suggesting a potential
role of the APOL1 risk variants in CVD. Studies to date on this
topic, however, have been conflicting. In a cross-sectional
analysis of SPRINT (Systolic Blood Pressure Intervention Trial),
an increasing number of APOL1 risk variants was not associ-
ated with prevalent clinical atherosclerotic CVD.20 In longitu-
dinal analyses of community-based blacks, postmenopausal
women, or older individuals, APOL1 risk variants have been
associated with increased cardiovascular morbidity.21,22 Other
longitudinal analyses in the general population and among
blacks with diabetes mellitus or hypertension, however, have
reported either no association with clinical CVD or even
reduced risk for subclinical CVD.23–25
Racial disparities in the incidence of CVD are well
described.26–29 In particular, the incidence of HF is much
higher among blacks compared with whites.26,27,29 Chronic
kidney disease has also been associated with an increased
risk of incident HF, especially among blacks.15 Whether
APOL1 risk variants partially explain the excess burden of HF
in blacks is not known.
In the present study, we aimed to determine whether the
APOL1 high-risk variants are associated with subclinical CVD,
incident clinical atherosclerotic CVD, and incident HF among
self-identified black participants of MESA (Multi-Ethnic Study
of Atherosclerosis).
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
MESA was a population-based cohort study designed to
investigate the pathogenesis of CVD, with an emphasis on
subclinical CVD progression. Details regarding the study
design of MESA have previously been published.30 Briefly,
6814 men and women of 4 racial/ethnic groups (white, black,
Hispanic, and Asian), aged 45 to 84 years, without baseline
clinical CVD or HF were recruited from 6 communities in the
United States (Baltimore, Maryland; Chicago, Illinois; Forsyth
County, North Carolina; Los Angeles County, California; New
York, New York; and St. Paul, Minnesota). Enrollment for the
first examination occurred between July 2000 and August
2002, followed by 4 more examinations: examination 2 (from
September 2002 to February 2004), examination 3 (from
March 2004 to September 2005), examination 4 (from
September 2005 to May 2007), and examination 5 (from
April 2010 to December 2011).30–32 Each participating MESA
site obtained approval from their institutional review board
and all participants provided informed consent.32 Among the
6814 participants, a total of 3217 (1746 black and 1471
Hispanic) were successfully genotyped for the APOL1 risk
variants. The APOL1 risk variants are extremely rare in people
of European descent.33,34 We excluded individuals of Hispanic
origin because of the relatively low prevalence of APOL1 risk
variants in this ethnic group and the potential for confounding
by ethnicity.35 Thus, our study population consisted of the
1746 self-identified black participants with available APOL1
genotyping.
Measurement of Outcomes
Measurements of subclinical CVD (coronary artery calcifica-
tion [CAC], carotid-intimal media thickness [CIMT], and left
ventricular mass) were obtained at baseline. Chest computed
tomography by either cardiac-gated electron-beam computed
tomography scanner (Chicago, Los Angeles, and New York) or
multidetector computed tomography (Baltimore, Forsyth
County, and St. Paul) was used to measure CAC. All scans
were read centrally by method of Agatston, with the average of
2 consecutive scans used to determine baseline CAC
score.30,31,36 We defined presence of CAC as having an
Agatston score greater than zero. CIMT was defined as the
mean of the maximum intimal-media thickness of the near and
far walls of the common carotid arteries, which were measured
by high-resolution B-mode ultrasound.30,31,37 Cardiac mag-
netic resonance imaging was performed at the baseline visit
using scanners with 1.5-T magnets, a 4-element, phased-array
surface coil placed anteriorly and posteriorly, ECG gating, and
brachial artery blood pressure (BP) monitoring.30 All images
were read centrally and left ventricular mass determined as
previously described.30,38
Clinical Perspective
What Is New?
• APOL1 high-risk variants may be associated with an
increased risk for incident heart failure but not subclinical
or incident clinical atherosclerotic disease.
What Are the Clinical Implications?
• Further clarification on the role of APOL1 high-risk variants
in heart failure is necessary to optimize the care of
individuals with this high-risk genetic background.
DOI: 10.1161/JAHA.117.007199 Journal of the American Heart Association 2
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Study participants were followed for clinical atherosclerotic
CVD and HF outcomes by telephone interviews every 9 to
12 months.39 All self-reported diagnoses were confirmed by
review of death certificates and medical records. Interviews
with physicians, next-of-kin, and friends were also conducted
to verify out-of-hospital deaths.30,39 Using predefined criteria,
each event was adjudicated by 2 independent reviewers. We
utilized a composite outcome of incident coronary heart
disease (CHD), which included myocardial infarction (MI),
definite or probable angina (if followed by revascularization),
resuscitated cardiovascular arrest, and CHD death. A diagno-
sis of MI was made based on a combination of symptoms,
ECG abnormalities, and changes in cardiac biomarker levels.
Angina was characterized by symptoms of ischemia plus
either physician diagnosis and treatment of angina or
objective imaging to support reversible myocardial ischemia
or obstructive coronary artery disease. CHD death was
specified by the occurrence of an MI within 28 days of death,
chest pain within 72 hours of death, or history of CHD without
a known noncardiac or nonatherosclerotic cause of death.
Stroke was defined as a neurologic deficit lasting for more
than 24 hours (or until death) with a clinically relevant brain
lesion on imaging.39,40 A diagnosis of congestive HF required
clinical signs or symptoms of congestive HF that were further
supported by physician diagnosis and treatment or imaging
(chest x-ray, echocardiogram, or ventriculography).40
Genotyping
The APOL1 risk variants (rs73885319 and rs71785313) were
genotyped using TaqMan assays (Applied Biosystems 7900)
and DNA samples (extracted from buffy coat) collected at the
baseline examination.4,5,30 Consistent with prior studies, G1
(risk allele for rs73885319 and rs60910145) is comprised of
2 missense mutations (S342G and I384M) and G2 (risk allele
for rs71785313) is characterized by a 6 base pair deletion
(del N388/Y389).4,5 We used a recessive genetic model,
defining the APOL1 high-risk genotypes as having 2 risk
alleles (G1/G1, G1/G2, or G2/G2) and the low-risk geno-
types as having 1 or no risk alleles (G1/G0, G2/G0,
G0/G0). Global African ancestry proportion was estimated
using 406 ancestry informative markers from the Affymetrix
6.0 array, and 4 ancestral populations in ADMIXMAP
software. The ancestry estimation was performed using
8227 European American, black, Hispanic, and Chinese
MESA and MESA Family participants.
Covariates
Details on demographic data, personal and family medical
histories, socioeconomic status, and medications were
obtained using questionnaires.30 Physical activity was
ascertained using the MESA Typical Week Physical Activity
Survey, which was adapted from the Cross-Cultural Activity
Participation Survey.30,41 At each visit, 3 resting BPs were
measured by trained personnel using a Dinamap model Pro
100 automated oscillometric sphygmomanometer (Critikon)
and the average of the last 2 measurements was used.30,41–43
Hypertension was defined as a systolic BP ≥140 mm Hg,
diastolic BP ≥90 mm Hg, or use of antihypertensive
medications.44 Measurements for lipid parameters were
performed at a central laboratory using blood that had been
collected after a 12-hour fast. Total and high-density lipopro-
tein cholesterol levels were measured using the cholesterol
oxidase method (Roche Diagnostics), triglycerides were
measured using the triglyceride GB reagent (Roche Diagnos-
tics), and low-density lipoprotein cholesterol was estimated
using the Friedewald equation (if triglycerides were
<400 mg/dL).42,43,45 Serum glucose was also measured
centrally from a fasting sample using the Vitros analyzer
(Johnson & Johnson Clinical Diagnostics, Inc).42 Diabetes
mellitus was defined as a fasting glucose ≥126 mg/dL or use
of glucose-lowering medications.46
Kidney function was assessed by measurement of cystatin
C from frozen serum specimens that had been stored at
70°C. As previously described, cystatin C was measured by
a particle-enhanced immunonephelometric assay (N Latex
Cystatin C, Siemens) on a nephelometer (BNII, Siemens) and
corrected for assay drift.47,48 Glomerular filtration was
estimated using the Chronic Kidney Disease-Epidemiology
Collaboration equation.49 Albuminuria, which we defined as a
urine albumin to creatinine ratio (UACR) ≥30 mg/g, was
measured from a single morning urine sample. Urinary
albumin was determined by nephelometry using the Array
360 CE Protein Analyzer (Beckman Instruments Inc), whereas
urinary creatinine was determined by the rate Jaffe method
using the Vitros 950IRC instrument (Johnson & Johnson
Clinical Diagnostics, Inc).47,50 Glomerular filtration rate (GFR)
was estimated at examinations 1, 3, 4, and 5, whereas UACR
was measured at examinations 1, 2, 3, and 5.
Statistical Analyses
Baseline demographic, socioeconomic, and clinical character-
istics were compared by APOL1 risk status (high versus low
risk) using means (SD), medians (interquartile range), or
counts (percentage). The cross-sectional associations
between APOL1 risk status and each measure of subclinical
CVD were then evaluated using linear or logistic regression.
CAC was assessed in 2 ways, by presence and by severity.
First, we categorized CAC as being either present (Agatston
score >0) or absent. Since the prevalence of CAC was high
(43% in our study population), the rare disease assumption
required for the odds ratio to be approximately equal to the
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relative risk (RR) is not met and odds ratios are likely to
overestimate RR. For each of the i participants, i=1, . . ., n, let
pi be the probability that the participant has a positive
Agatston score (CAC >0) and xi be a vector of predictors; the
logistic regression postulates pi ¼ expðxTi bÞ=ð1þ expðxTi bÞÞ.
The parameters b, when exponentiated, are interpreted as
odds ratios. To avoid the frequent misinterpretation of the
odds ratio as an estimate of the RR, we modeled the RR
directly by expressing pi ¼ expðxTi bÞ. The parameters b, when
exponentiated, are interpreted as RRs, this is the RR
regression model. In this model, the error distribution is
binomial conditional on the vector of covariates, x. Thus, the
efficient model for estimating the coefficients is the model
that uses what is termed the log link with binomial error.51–53
Second, among participants with detectable CAC, we exam-
ined the association between APOL1 risk status and severity
of calcification [ln(Agatston score)] using linear regression
models. CIMT and left ventricular mass were assessed as
continuous variables, also using linear regression models. For
these analyses, we constructed a series of models: (1) model
1: unadjusted model; (2) model 2: adjusted for age, sex, and
African ancestry; (3) model 3a: model 2+baseline hyperten-
sion; (4) model 3b: model 2+time-updated cystatin C–based
estimated GFR and log-transformed UACR; and (5) model 3c:
model 2+baseline hypertension+time-updated cystatin C–
based estimated GFR and log-transformed UACR. Given that
genotypes are unlikely to be confounded by clinical conditions
that develop later in life, we treated model 2 as our final
model. Furthermore, models 3a–c were intended to assess for
mediation by BP and/or kidney disease, so these models
were only utilized when a main effect was observed. We then
used Cox proportional hazards models to study the longitu-
dinal association between APOL1 risk status and incident MI,
stroke, CHD, and HF. A similar set of nested models was
applied to these analyses. The proportional hazards assump-
tion was checked using Schoenfeld residuals. In sensitivity
analyses, we repeated the above analyses using additive and
dominant genetic models. No adjustments were made for
multiple comparisons, as our a priori hypothesis focused on
these specific outcomes.54 Statistical analyses were per-
formed using SPSS version 24 (IBM Corp). P values <0.05
were considered to be statistically significant.
Results
Baseline Characteristics
Among 6814 MESA participants, 1746 were black and had
APOL1 genotyping available. Of these 1746 individuals
included in our study population, 762 (44%), 771 (44%), and
213 (12%) had 0, 1, and 2 APOL1 risk alleles, respectively.
Therefore, when considering a recessive genetic model, 213
(12%) had the APOL1 high-risk genotypes (2 risk alleles), and
1533 (88%) had the low-risk genotypes (0 or 1 risk allele). At
baseline, the mean age was 62 years, 55% were women,
mean cystatin C–based estimated GFR was 89 mL/min per
1.73 m2, and 12% had albuminuria (defined as a UACR
≥30 mg/g). Compared with the APOL1 high-risk group, more
individuals in the low-risk group had a family history of heart
disease. Otherwise, the 2 APOL1 risk groups were similar at
baseline (Table 1).
Coronary Artery Calcium
At baseline, 758 (43%; 77 APOL1 high-risk and 681 APOL1
low-risk) individuals had evidence of CAC. In unadjusted
analyses, individuals with the APOL1 high-risk genotypes were
19% less likely to have a CAC score >0 compared with those
with the low-risk genotypes (model 1: RR, 0.81; 95%
confidence interval [CI], 0.67–0.98). This difference, however,
was no longer statistically significant once African ancestry,
age, and sex were added to the model (model 2: adjusted RR,
0.88; 95% CI, 0.75–1.03). Among individuals with detectable
CAC, the APOL1 high-risk genotypes were not significantly
associated with CAC severity (model 2: adjusted relative
difference, 1.41; 95% CI, 0.93–2.16) (Table 2). Similar con-
clusions were obtained when using an additive or dominant
genetic model (Table S1).
Common CIMT
Baseline common CIMT, another measure of subclinical
atherosclerosis, was similar between APOL1 high- and low-
risk individuals (mean 0.92 and 0.90 mm, respectively). In
unadjusted analyses and analyses adjusted for African
ancestry, age, and sex, there was no significant difference
in severity of CIMT by APOL1 risk status (Table 2). The use of
an additive or dominant genetic model yielded similar results
(Table S1).
Left Ventricular Mass
Left ventricular mass was similar between APOL1 high- and
low-risk individuals at baseline (mean 162 g versus 158 g,
respectively). When considering recessive, additive, and
dominant genetic models, the APOL1 high-risk variants were
not significantly associated with left ventricular mass
(Table 2; Table S1).
Incident CVD Events
Over a mean follow-up of 11.4 years, 125 (7%) individuals
developed the composite outcome of incident CHD. Incident
MI and stroke occurred in 47 (3%) and 65 (4%) individuals,
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respectively. There was no significant difference in risk for
incident CHD, MI, or stroke by APOL1 risk status (Table 3;
Table S2).
Eighty individuals (15 APOL1 high-risk and 65 APOL1 low-
risk) developed incident HF. We found that individuals with the
APOL1 high-risk genotypes were 82% more likely to develop
HF compared with individuals with the low-risk genotypes
(model 2: adjusted hazard ratio, 1.82; 95% CI, 1.01–3.28).
This association was not fully explained by differences in
baseline hypertension status and markers of kidney function.
Adding hypertension only slightly attenuated the APOL1-
associated risk for incident HF (model 3a: adjusted hazard
ratio, 1.80; 95% CI, 1.00–3.24), whereas adding cystatin C–
based estimated GFR and UACR did not change the associ-
ation (model 3b: adjusted hazard ratio, 1.86; 95% CI, 1.03–
3.35; Table 4). Finally, in sensitivity analyses, similar trends
were noted when using an additive genetic model (model 2:
adjusted hazard ratio, 1.41; 95% CI, 1.01–1.97), whereas no
statistically significant association was detected when using a
dominant genetic model (Table S3).
Discussion
In this study of black people without baseline clinical CVD, we
report that the APOL1 risk variants were not associated with
subclinical measures of CVD, including CAC, CIMT, and left
ventricular mass or incident clinical atherosclerotic events. On
the other hand, we found that the APOL1 high-risk genotypes
were significantly associated with an increased risk for
incident HF compared with the low-risk genotypes. This
association was not explained by the presence of hyperten-
sion or kidney function abnormalities at baseline. Our results
add to the growing body of literature on the potential role of
APOL1 in atherosclerotic CVD and HF.
To date, few studies have examined whether the APOL1 risk
variants relate to subclinical CVD. In both JHS (Jackson Heart
Study) and AA-DHS (African American-Diabetes Heart Study),
individuals with APOL1 risk variants were noted to have less
calcium plaque burden in their coronary (JHS, 2 versus 0 risk
alleles) and carotid (AA-DHS, 1 or 2 versus 0 risk alleles)
arteries.21,23 We similarly found that APOL1 high-risk individ-
uals were less likely to have CAC present compared with low-
risk individuals; however, our results were not statistically
significant. Varied modeling strategies and populations across
the 3 studies may account for these differences. We also
reported that the APOL1 high-risk genotypes were not asso-
ciated with CIMT severity. These findings are consistent with
CHS (Cardiovascular Health Study), a cohort of older individ-
uals, and the only other study we are aware of that has
examined this potential association.22 In addition, we found no
significant association between the APOL1 risk variants and left
ventricular mass.
Table 1. Baseline Characteristics of Study Population, by
APOL1 Risk Status
Characteristic
APOL1 Low-Risk
(n=1533)
APOL1
High-Risk (n=213)
Age, y 6210 6210
Women 847 (55) 105 (49)
Education
Less than high school 171 (11) 32 (15)
High school graduate 304 (20) 38 (18)
Post-secondary education 1045 (69) 142 (67)
Employment
Employed 610 (40) 83 (39)
Unemployed/employed
part-time
114 (8) 22 (10%)
Retired/homemaker 795 (52) 107 (51)
Annual family income
<$25 000 429 (30) 59 (30)
$25 000 to $49 999 462 (33) 61 (31)
$50 000 to $74 999 276 (20) 39 (20)
≥$75 000 247 (18) 35 (18)
Smoking status
Never 692 (46) 99 (47)
Former 545 (36) 72 (34)
Current 274 (18) 41 (19)
Body mass index, kg/m2 30.25.9 30.05.9
Diabetes mellitus 257 (17) 46 (22)
Fasting glucose, mg/dL 10032 10233
Hypertension 897 (59) 134 (63)
Systolic BP, mm Hg 13222 13121
Diastolic BP, mm Hg 7411 7510
Use of antihypertensive
medications
757 (49) 116 (55)
Total cholesterol, mg/dL 19036 19037
LDL, mg/dL 11733 11534
HDL, mg/dL 5215 5416
Triglyceride, mg/dL 90 [66–123] 88 [67–122]
Use of lipid-lowering
medications
237 (16) 39 (18)
Moderate-vigorous PA
(MET, min/wk)
4560 [2110–8640] 4560 [2258–8505]
Family history of heart
disease, No. (%)
612 (43) 70 (34)
eGFRCysC, mL/min per
1.73 m2
8920 8920
UACR, mg/g 5.4 [3.1–12.5] 6.2 [3.5–15.6]
UACR ≥30 mg/g 169 (11) 33 (16)
Values are presented as meanSD, median [interquartile range], or number
(percentage). APOL1 high-risk defined as 2 risk alleles and low-risk defined as 0 or 1 risk
allele. BP indicates blood pressure; eGFRCysC, cystatin C–based estimated glomerular
filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic
equivalent; PA, physical activity; UACR, urine albumin to creatinine ratio.
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In further analyses, we considered clinical atherosclerotic
CVD separate from congestive HF because their underlying
disease mechanisms likely differ. We found no association
between the APOL1 risk variants and incident MI, coronary
heart disease, or stroke. These findings are in accordance
with results from the ARIC (Atherosclerosis Risk in Commu-
nities) study and SPRINT trial, which also reported no
significant association between the APOL1 high-risk variants
and incident or prevalent CVD, respectively.20,25 On the other
hand, the JHS and WHI (Women’s Health Initiative) both
demonstrated a significantly increased risk for a major
adverse cardiovascular event among people with 2 versus 0
APOL1 high-risk alleles,21 whereas the CHS noted an
increased risk of MI but not stroke or cardiovascular
Table 2. Cross-Sectional Associations of APOL1 Risk Variants With Subclinical Cardiovascular Disease Measures at the Baseline
Examination in MESA
No. CAC >0
Model 1 Model 2
RR (95% CI) RR (95% CI)
CAC
APOL1 low-risk 1533 681 (44%) 1.00 (reference) 1.00 (reference)
APOL1 high-risk 213 77 (36%) 0.81 (0.67–0.98) 0.88 (0.75–1.03)
No. Geometric meanSD
Model 1 Model 2
RD* (95% CI) RD* (95% CI)
APOL1 low-risk 681 667 1.00 (reference) 1.00 (reference)
APOL1 high-risk 77 696 1.54 (0.98–2.41) 1.41 (0.93–2.16)
No. MeanSD
Model 1 Model 2
b (95% CI) b (95% CI)
CIMT
APOL1 low-risk 1533 0.900.19 mm 0 (reference) 0 (reference)
APOL1 high-risk 213 0.920.20 mm 0.02 (0.01 to 0.05) 0.01 (0.02 to 0.04)
Left ventricular mass
APOL1 low-risk 1054 15841 g 0 (reference) 0 (reference)
APOL1 high-risk 152 16244 g 4.29 (3.26 to 11.84) 0.69 (5.58 to 6.96)
APOL1 high-risk defined as 2 risk alleles and low-risk defined as 0 to 1 risk alleles. Model 1: unadjusted; model 2: adjusted for age, sex, and African ancestry. CI indicates confidence
interval; CIMT, carotid-intimal media thickness; MESA, Multi-Ethnic Study of Atherosclerosis; RD, relative difference; RR, relative risk.
*Relative difference in geometric mean coronary artery calcification (CAC) score for APOL1 high- vs low-risk, as estimated from a linear regression with ln(CAC score) as the dependent
variable.
Table 3. Association of APOL1 Risk Variants With Incident Cardiovascular Disease Events in MESA
No.
Rate Model 1 Model 2
% Per Year HR (95% CI) HR (95% CI)
Incident CHD (composite)
APOL1 low-risk 1532 0.7 1.00 (reference) 1.00 (reference)
APOL1 high-risk 213 0.7 0.97 (0.54–1.73) 0.99 (0.55–1.78)
Incident MI
APOL1 low-risk 1532 0.2 1.00 (reference) 1.00 (reference)
APOL1 high-risk 213 0.3 1.24 (0.52–2.94) 1.23 (0.51–2.96)
Incident stroke
APOL1 low-risk 1532 0.3 1.00 (reference) 1.00 (reference)
APOL1 high-risk 213 0.4 1.00 (0.45–2.20) 1.02 (0.46–2.25)
Coronary heart disease (CHD) defined by myocardial infarction (MI), definite or probable angina (if followed by revascularization), resuscitated cardiovascular arrest, and CHD death. APOL1
high-risk defined as 2 risk alleles and low-risk defined as 0 or 1 risk allele. Model 1: unadjusted; model 2: adjusted for age, sex, and African ancestry. CI indicates confidence interval; HR,
hazard ratio; MESA, Multi-Ethnic Study of Atherosclerosis.
DOI: 10.1161/JAHA.117.007199 Journal of the American Heart Association 6
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mortality.22 The reasons for these discrepant findings are
unclear, although differences in study populations likely
contribute, including varying ages and comorbidities.20–22,25
Our study is one of few to examine the association of
APOL1 with incident HF. We found that people with the
APOL1 high-risk genotypes were more likely to develop HF
compared with the low-risk genotypes. Prior studies have
demonstrated that incident HF is much more common in
blacks compared with whites.26,27 While this difference in
risk has primarily been attributed to the higher burden of
traditional cardiovascular risk factors among blacks, perhaps
risk variants in the APOL1 gene contribute as well.26,27,29
Upon further investigation, we found that this association
between APOL1 high-risk status and incident HF was only
slightly attenuated by hypertension and not at all by kidney
function markers. APOL1 expression is driven by inflamma-
tion, and its protein product has been found in endothelial
and vascular smooth muscle cells within the kidney.16,55
Among individuals with decompensated HF, different variants
in the APOL1 gene have been associated with differential
responsiveness to furosemide-based diuretic regimens, and
whether differences in response to medications may explain
observed associations is not known.56 Perhaps the APOL1
risk variants increase risk for HF via endothelial dysfunction
or abnormalities in cardiac remodeling. Alternatively, the
APOL1 risk variants may be associated with HF caused by
effects on the kidney that are not sufficiently captured by
traditional clinical markers or by causing defects in sodium
handling. Our significant results for congestive HF should be
interpreted with caution. Although increased left ventricular
mass would have potentially explained the association
between the APOL1 risk variants and incident HF risk in
MESA,57 we did not find an association between the risk
variants and left ventricular mass. Unlike our study, the CHS
reported no difference in risk of incident congestive HF
between APOL1 high- and low-risk individuals. The CHS
cohort, however, consisted of much older individuals with a
mean age of 73 years.22 Further studies are needed to
clarify the role of the APOL1 high-risk variants in HF, and the
findings of this study need replication. Distinctions should
also be made between HF with preserved versus reduced
ejection fraction, as the pathogeneses of these 2 types of
HF are different.
Study Strengths and Limitations
Our study has several strengths. First, we utilized data from a
well-described cohort of individuals. Second, follow-up was
extensive, with a mean duration of 11 years. Third, CAC,
CIMT, and left ventricular mass were collected in a standardized
manner while all clinical atherosclerotic CVD and HF events
were adjudicated using prespecified criteria. Finally, our study
population was free of clinical CVD at baseline, thus allowing us
to examine the variants’ associations with first incident CVD
event. Limitations include the relatively small number of events,
limiting our power to detect small to moderate effect sizes. In
addition, our analyses on subclinical CVD were cross-sectional.
Still, our findings on CAC, CIMT, and left ventricular mass
provide insight on potential mechanisms by which the APOL1
risk variants are hypothesized to cause CVD. While it is possible
to have copy number variation at the APOL1 locus, these are
very rare, and thus we are unable to test associations of
additional possible genotypes with outcomes. Finally, the
multiple models could lead to multiple comparisons problems
and subsequent false-positive findings.
Conclusions
We report that the APOL1 high-risk variants are not associ-
ated with subclinical or clinical atherosclerotic CVD; however,
they may be associated with an increased risk of incident HF.
Given that the APOL1 risk variants are associated with chronic
kidney disease, a known risk factor for CVD and HF, clarifying
the role of APOL1 high-risk alleles in subclinical, clinical
atherosclerotic CVD, and HF is of utmost importance.
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SUPPLEMENTAL MATERIAL 
Table S1. Cross-sectional associations of APOL1 risk variants with subclinical cardiovascular disease 
measures at the baseline exam in the Multi-Ethnic Study of Atherosclerosis (MESA) using additive (per 
additional APOL1 risk allele) and dominant (0 versus 1-2 APOL1 risk alleles) genetic models. 
Coronary Artery Calcification (CAC) 
   Model 1 Model 2 
 n CAC >0 RR (95% CI) RR (95% CI) 
Per additional APOL1 risk 
allele 
1746 758 (43%) 0.94 (0.87, 1.01) 0.96 (0.90, 1.03) 
0 APOL1 risk alleles 762 339 (45%) 1.00 (ref) 1.00 (ref) 
1-2 APOL1 risk alleles 984 419 (43%) 0.96 (0.86, 1.07) 0.98 (0.89, 1.08) 
   Model 1 Model 2 
 n Geometric mean 
(SD)  
RD* (95% CI) RD* (95% CI) 
Per additional APOL1 risk 
allele 
758 69 ± 6 1.13 (0.91, 1.39) 1.14 (0.93, 1.39) 
0 APOL1 risk alleles 339 65 ± 6 1.00 (ref) 1.00 (ref) 
1-2 APOL1 risk alleles 419 72 ± 6 1.05 (0.80, 1.38) 1.10 (0.85, 1.43) 
Carotid Intimal-Media Thickness (CIMT) 
   Model 1 Model 2 
 n Mean (SD) β (95% CI) β (95% CI) 
Per additional APOL1 risk 
allele 
1746 0.91 ± 0.19 mm 0.004 (-0.01, 0.02) -0.0001 (-0.01, 0.01) 
0 APOL1 risk alleles 762 0.91 ± 0.19 mm 0 (ref) 0 (ref) 
1-2 APOL1 risk alleles 984 0.90 ± 0.20 mm 0.001 (-0.02, 0.02) -0.004 (-0.02, 0.01) 
Left Ventricular Mass 
   Model 1 Model 2 
 n Mean (SD) β (95% CI) β (95% CI) 
Per additional APOL1 risk 
allele 
1206 159 ± 42 g  1.35 (-2.30, 4.99) 0.62 (-2.44, 3.68) 
0 APOL1 risk alleles 526 158 ± 41 g 0 (ref) 0 (ref) 
1-2 APOL1 risk alleles 680 159 ± 42 g 0.65 (-4.34, 5.63) 0.85 (-3.33, 5.03) 
Abbreviations: RR=relative risk; RD=relative difference; CI=confidence interval; ref=reference. 
Model 1: unadjusted; Model 2: adjusted for age, sex, and African ancestry.  
*Relative difference in geometric mean CAC score for APOL1 high- vs. low-risk, as estimated from a 
linear regression with ln(CAC score) as the dependent variable.   
  
Table S2. Association of APOL1 risk variants with incident cardiovascular disease events in the Multi-
Ethnic Study of Atherosclerosis (MESA) using additive (per additional APOL1 risk allele) and dominant (0 
versus 1-2 APOL1 risk alleles) genetic models. 
Incident Coronary Heart Disease (Composite) 
   Model 1 Model 2 
 n # of events HR (95% CI) HR (95% CI) 
Per additional APOL1 risk 
allele 
1745 125 0.92 (0.70, 1.21) 0.96 (0.73, 1.28) 
0 APOL1 risk alleles 762 59 1.00 (ref) 1.00 (ref) 
1-2 APOL1 risk alleles 983 66 0.87 (0.60, 1.26) 0.94 (0.64, 1.37) 
Incident Myocardial Infarction 
   Model 1 Model 2 
 n # of events HR (95% CI) HR (95% CI) 
Per additional APOL1 risk 
allele 
1745 47 1.18 (0.76, 1.84) 1.23 (0.79, 1.92) 
0 APOL1 risk alleles 762 19 1.00 (ref) 1.00 (ref) 
1-2 APOL1 risk alleles 983 28 1.25 (0.67, 2.33) 1.35 (0.72, 2.56) 
Incident Stroke 
   Model 1 Model 2 
 n # of events HR (95% CI) HR (95% CI) 
Per additional APOL1 risk 
allele 
1745 65 1.06 (0.73, 1.55) 1.09 (0.74, 1.60) 
0 APOL1 risk alleles 762 27 1.00 (ref) 1.00 (ref) 
1-2 APOL1 risk alleles 983 38 1.12 (0.66, 1.88) 1.16 (0.68, 1.98) 
Coronary Heart Disease (CHD) defined by myocardial infarction, definite or probable angina (if followed 
by revascularization), resuscitated cardiovascular arrest, and CHD death. 
Model 1: unadjusted; Model 2: adjusted for age, sex, and African ancestry.   
Abbreviations: CI=confidence interval; ref=reference. 
 
 
  
Table S3. Association of APOL1 risk variants with incident heart failure in the Multi-Ethnic Study of 
Atherosclerosis (MESA) using additive (per additional APOL1 risk allele) and dominant (0 versus 1-2 
APOL1 risk alleles) genetic models. 
 Additive Genetic 
Model 
Dominant Genetic 
Model 
Per additional APOL1 
risk allele 
1-2 vs. 0 APOL1  
risk alleles  
Hazard Ratio  
(95% CI) 
Hazard Ratio  
(95% CI) 
Model 1: unadjusted 1.36 
(0.98, 1.88) 
1.35 
(0.84, 2.16) 
Model 2: adjusted for age, sex, and African 
ancestry 
1.41  
(1.01, 1.97) 
1.43 
(0.88, 2.31) 
Model 3a: Model 2 + hypertension only 1.41 
(1.01, 1.96) 
1.43  
(0.88, 2.32) 
Model 3b: Model 2 + eGFRCysC + UACR only 1.45 
(1.04, 2.03) 
1.49  
(0.92, 2.44) 
Model 3c: Model 2 + hypertension + eGFRCysC + 
UACR  
1.45  
(1.04, 2.02) 
1.49 
(0.91, 2.43) 
Abbreviations: CI=confidence interval; ref=reference; eGFRCysC=estimated cystatin-c based glomerular 
filtration rate; UACR=urine albumin-to-creatinine ratio.  
eGFR was measured at Exams 1, 3, 4, and 5. UACR was measured at Exams 1, 2, 3, and 5.  
 
 
 
